Expertise in
8
conditions

Boris Guiu

St Eloi University Hospital
Montpellier, FR 
Expertise in
8
conditions
St Eloi University Hospital
Montpellier, FR 

Overview

Boris Guiu practices practicing medicine in Montpellier, France.

Mr. Guiu is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Liver Cancer, Enlarged Liver, Liver Failure, Liver Embolization, and Hepatectomy.

He is actively involved in clinical research, co-authoring 225 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

St Eloi University Hospital
Montpellier, France
Other Locations
CHU Nice
Nice, France
CHU Besancon
Besancon, France
Dijon, France
Montpellier, Avenue Emile Bertin Sans, Soisy-sous-montmorency, 34000, France
Clermont-ferrand, France
Villejuif, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Device
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
Enrollment Status: Completed
Publish Date: July 04, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients
Enrollment Status: Completed
Publish Date: April 21, 2022
Intervention Type: Procedure, Biological
Study Phase: Not Applicable
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
Multicenter Study to Evaluate the Safety and Performance of the Quantum Surgical Robotic Device for Image-guided Percutaneous Needle Placement
Multicenter Study to Evaluate the Safety and Performance of the Quantum Surgical Robotic Device for Image-guided Percutaneous Needle Placement
Enrollment Status: Completed
Publish Date: February 04, 2021
Intervention Type: Device
Study Phase: Not Applicable
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Device
View 6 Less Clinical Trials

225 Total Publications

The Safety Standards for Liver Percutaneous Thermal Ablation: A Meta-Analysis of Adverse Events over 15 Years.
The Safety Standards for Liver Percutaneous Thermal Ablation: A Meta-Analysis of Adverse Events over 15 Years.
Journal: Radiology
Published: March 24, 2026

Frequently Asked Questions about Boris Guiu

Is Boris Guiu a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Boris Guiu is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Boris Guiu participate in research or clinical trials?

Yes. Boris Guiu has published 225 articles and abstracts on conditions like Liver Cancer. You can view a list of Boris Guiu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guiu's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile